Adults with juvenile arthritis carry a heavier long-term burden

Design

Nationwide register-based matched cohort study (Norway)

Population

2,932 adults with juvenile idiopathic arthritis vs 29,097 matched comparators

Primary outcome

Comorbidity prevalence and all-cause mortality

Effect

Higher hypertension (3.6% vs 1.4%) and other comorbidities; mortality 2.4 vs 1.8 per 1000 person-years

Juvenile idiopathic arthritis does not simply resolve at adulthood, and its long-term systemic toll is under-recognised. This nationwide Norwegian register study matched 2,932 adults with juvenile idiopathic arthritis to 29,097 general-population comparators.

Adults with the condition had higher five-year prevalences of several comorbidities: hypertension (3.6% vs 1.4%), type 1 diabetes (1.7% vs 0.7%), chronic kidney disease (0.5% vs 0.2%), coeliac disease (1.4% vs 0.7%) and autoimmune thyroiditis, alongside more ischaemic heart disease. All-cause mortality was higher than in comparators (2.4 vs 1.8 per 1000 person-years). Comorbidity and mortality were similar whether or not patients had recent DMARD exposure.

The message for practice is to treat adults with juvenile idiopathic arthritis as a higher-risk group needing active cardiovascular and metabolic surveillance and screening for associated autoimmune disease, not as people who have simply outgrown a childhood illness. The lack of difference by DMARD exposure should not be read as the drugs being harmful or protective, given confounding by disease severity.

• Nationwide study of 2,932 adults with juvenile idiopathic arthritis versus 29,097 matched comparators.
• Higher prevalence of hypertension (3.6% vs 1.4%), type 1 diabetes, chronic kidney disease and coeliac disease.
• All-cause mortality was higher (2.4 vs 1.8 per 1000 person-years).
• Comorbidity and mortality were similar with or without recent DMARD exposure.
• Give these adults active cardiovascular, metabolic and autoimmune surveillance.

Why it matters

It reframes juvenile arthritis as a lifelong condition with measurable excess mortality, changing how adult follow-up should be approached.

Don't overread it

This was retrospective register data; the comorbidity and mortality links are associations, and the lack of a DMARD-exposure difference is confounded by disease severity.

The statistics, in plain English

These are register-based prevalence and mortality comparisons, so they show a real excess burden but cannot attribute it to a cause; the absence of a DMARD-exposure difference is vulnerable to confounding by indication and should not be read as a drug effect.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.